目的探讨孟鲁司特联合吸入糖皮质激素治疗小儿慢性中度持续支气管哮喘的临床疗效。方法选择宾阳县宾州镇芦圩卫生院2014年1月—2015年1月收治的80例小儿慢性中度持续支气管哮喘患儿,随机分为对照组和试验组,各40例。对照组患儿给予吸入布地奈德治疗,试验组患儿给予孟鲁司特联合吸入糖皮质激素治疗,比较两组患儿炎性指标〔半胱氨酰白三烯(Cys LTs),IL-5〕,症状发作时间、次数、评分。结果治疗前两组患儿Cys LTs和IL-5比较,差异无统计学意义(P>0.05);治疗后试验组患儿Cys LTs和IL-5低于对照组,差异有统计学意义(P<0.05)。试验组症状发作次数少于对照组,发作时间短于对照组,差异有统计学意义(P<0.05)。咳嗽评分时间和方法无交互作用(P>0.05);时间间比较,差异有统计学意义(P<0.05);组间比较,差异有统计学意义(P<0.05)。日间症状评分时间和方法无交互作用(P>0.05);时间间比较,差异有统计学意义(P<0.05);组间比较,差异有统计学意义(P<0.05)。夜间症状评分时间和方法无交互作用(P>0.05);时间间比较,差异有统计学意义(P<0.05);组间比较,差异有统计学意义(P<0.05)。治疗前两组患儿咳嗽评分、日间症状评分、夜间症状评分比较,差异无统计学意义(P>0.05),治疗4周和治疗3个月后试验组咳嗽评分、日间症状评分、夜间症状评分低于对照组,差异有统计学意义(P<0.05)。试验组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论孟鲁司特联合吸入糖皮质激素治疗小儿慢性中度持续支气管哮喘的临床疗效确切,有效改善患儿症状。 Objective To investigate the clinical efficacy of montelukast combined inhaled corticosteroids in the treatment of children with chronic moderate persistent bronchial asthma. Methods Eighty children with chronic moderate persistent bronchial asthma admitted from January 2014 to January 2015 in Luwei Sanitary Hospital of Binzhou, Binyang were randomly divided into control group and experimental group, 40 cases in each group. Children in the control group were treated with budesonide inhalation. Patients in the test group were given montelukast in combination with glucocorticoid therapy. Inflammatory markers (Cys LTs, IL- 5], symptoms of attack time, frequency, score. Results There was no significant difference in Cys LTs and IL-5 between the two groups before treatment (P> 0.05). After treatment, Cys LTs and IL-5 in the experimental group were lower than those in the control group (P <0.05). The frequency of symptom onset in the experimental group was less than that in the control group, and the onset time was shorter than that in the control group (P <0.05). There was no interaction between cough score and time (P> 0.05). There was significant difference in time between the two groups (P <0.05). There was significant difference between groups (P <0.05). There was no interaction between daytime symptom score and time (P> 0.05). There was significant difference in time between the two groups (P <0.05). There was significant difference between the two groups (P <0.05). There was no interaction between nighttime symptom score and time (P> 0.05). There was significant difference in time between the two groups (P <0.05). There was significant difference between groups (P <0.05). Cough score, daytime symptom scores and nocturnal symptom scores were not significantly different between the two groups before treatment (P> 0.05). After 4 weeks of treatment and 3 months of treatment, cough score, daytime symptom score, nighttime Symptoms were lower than the control group, the difference was statistically significant (P <0.05). The incidence of adverse reactions in the experimental group was lower than that in the control group, the difference was statistically significant (P <0.05). Conclusion Montelukast combined inhaled corticosteroids in children with chronic moderate persistent bronchial asthma clinical curative effect is exact, effectively improve children’s symptoms.